...
首页> 外文期刊>Vaccine >Construction and immunogenicity of recombinant adenovirus expressing the capsid protein of porcine circovirus 2 (PCV2) in mice
【24h】

Construction and immunogenicity of recombinant adenovirus expressing the capsid protein of porcine circovirus 2 (PCV2) in mice

机译:表达小鼠圆环病毒2(PCV2)衣壳蛋白的重组腺病毒的构建及免疫原性

获取原文
获取原文并翻译 | 示例
           

摘要

Porcine circovirus 2 (PCV2) has been implicated as the etiological agent of some diseases, mainly postweaning multisystemic wasting syndrome (PMWS) and porcine dermatitis and nephropathy syndrome (PDNS). The capsid (Cap) protein encoded by the PCV2 ORF2 gene may be an excellent candidate for vaccination. In this study, the Cap protein gene was amplified by PCR, and cloned into the transfer vector pShuttle-CMV. After co-transformation of PmeI-linearized recombinant plasmid pShuttle-CMV-ORF2 and the bone vector pAdEasy-1 into Escherichia coli bacteria strain BJ5183, recombinant plasmid containing Cap protein gene (pAd-ORF2) was obtained and identified with PCR. Upon transfection of PacI-linearized plasmid pAd-ORF2 in 293 cell line, a recombinant adenovirus was obtained and named as rAd-Cap with viral titer of 10(13.0) TCID(50)/ml. The expression of the Cap protein in the 293 cells infected with rAd-Cap was confirmed with specific antibody to PCV2 by Western blotting and IPMA. Mice were inoculated with 10(8), 10(10) and 10(12) TCID(50)/mouse of rAd-Cap and boosted 2 weeks later, and they could generate antibody against PCV2 detected by indirect ELISA, Western blot and neutralizing activity assay. It indicated that the rAd-Cap was able to express the capsid of PCV2 and could elicit immune responses against the PCV2 in mice. The recombinant adenovirus might be an attractive candidate vaccine for preventing the disease associated with PCV2 infection.
机译:猪圆环病毒2(PCV2)被认为是某些疾病的病原体,主要是断奶后多系统消耗综合症(PMWS)和猪皮炎和肾病综合症(PDNS)。由PCV2 ORF2基因编码的衣壳(Cap)蛋白可能是接种疫苗的理想候选者。在这项研究中,通过PCR扩增Cap蛋白基因,并将其克隆到转移载体pShuttle-CMV中。将PmeI线性化的重组质粒pShuttle-CMV-ORF2和骨载体pAdEasy-1共转化为大肠杆菌BJ5183菌株后,获得了含有Cap蛋白基因(pAd-ORF2)的重组质粒,并进行了PCR鉴定。在293细胞系中转染PacI线性化质粒pAd-ORF2后,获得了重组腺病毒,并将其命名为rAd-Cap,病毒滴度为10(13.0)TCID(50)/ ml。通过针对PCV2的特异性抗体,通过Western印迹和IPMA证实了被rAd-Cap感染的293细胞中Cap蛋白的表达。小鼠分别以10(8),10(10)和10(12)TCID(50)/小鼠的rAd-Cap接种并加强免疫,两周后它们可以产生通过间接ELISA,Western印迹和中和检测到的针对PCV2的抗体活性测定。这表明rAd-Cap能够表达PCV2的衣壳,并且可以在小鼠中引发针对PCV2的免疫应答。重组腺病毒可能是预防PCV2感染相关疾病的有吸引力的候选疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号